Company Encyclopedia
View More
name
Hinova
688302.SH
Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company’s products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late-stage cancers; and HP518, an oral PROTAC drug in phase I clinical trials with a focus on to solve the drug resistance of AR-mutated prostate cancer. Hinova Pharmaceuticals Inc.
3.144 T
688302.SHMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking150/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-12.40%D
    • Profit Margin-612.36%E
    • Gross Margin99.62%A
  • Growth ScoreB
    • Revenue YoY21414.67%A
    • Net Profit YoY31.22%B
    • Total Assets YoY-2.96%D
    • Net Assets YoY-10.61%D
  • Cash ScoreB
    • Cash Flow Margin-16.33%D
    • OCF YoY21414.67%A
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreA
    • Gearing Ratio19.24%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Two major industries' stocks cluster in the gross margin ranking, with 27 stocks having a gross margin exceeding 90% in the first half of the year

    According to statistics, excluding the financial industry, the food and beverage industry had a gross profit margin of 51.41% in the first half of 2023, continuing to rank first. The beauty and personal care and media industries ranked second and third, respectively. The pharmaceutical and biotechnology and computer industries had outstanding individual stock performances, with Hinova ranking first with a gross profit margin of 99.52%, and a total of 27 individual stocks had gross profit margins exceeding 90%

    Zhitong·
    SH
    688302
    -0.57%
    Zhitong·
    SH
    688302
    -0.57%

    The concept of innovative drugs fluctuates and rebounds, JZT hits the limit up

    The concept of innovative drugs has rebounded, with JZT hitting the daily limit, Hinova, RemeGen, and Shenzhou Cell rising over 10%, while Fuyuan Pharmaceutical, Kangchen Pharmaceutical, Guangshengtang, and Nuo Cheng Jianhua are among the top gainers

    Zhitong·
    SZ
    000989
    +0.66%
    SH
    688302
    -0.57%
    SH
    688331
    +1.42%
    Zhitong·
    SZ
    000989
    +0.66%
    SH
    688302
    -0.57%
    SH
    688331
    +1.42%

    Hinova Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 61.85 million yuan

    Hinova released its 2025 semi-annual report, with revenue of 13.17 million yuan, a year-on-year increase of 11,899.08%. The net loss attributable to the parent company was 61.85 million yuan, and the net profit excluding non-recurring items was a loss of 73.01 million yuan, with basic earnings per share of -0.62 yuan. The significant revenue growth was mainly due to the launch of the new drug deuterated enzalutamide soft capsules, with sales revenue reaching 13.0688 million yuan

    Zhitong·
    SH
    688302
    -0.57%
    Zhitong·
    SH
    688302
    -0.57%

    Caitong Securities: Multiple new innovative drugs have emerged in the field of gout, focusing on companies related to uric acid reduction and acute phase relief treatment

    Caitong Securities released a research report indicating that there are many gout patients in China, accounting for over 30% of the global total. In terms of uric acid-lowering treatment, the clinical research competition for URAT1 inhibitors is intense, while acute phase relief treatment focuses on IL-1β inhibitors. It is recommended to pay attention to related companies, including ApicHope, LIVZON GROUP, and Hinova. Gout treatment is divided into acute and stable phases, with acute phase treatment primarily using colchicine and non-steroidal anti-inflammatory drugs, while uric acid-lowering treatment includes various medications

    Zhitong·
    SH
    688302
    -0.57%
    SZ
    000513
    -0.45%
    HK
    01513
    -1.17%
    Zhitong·
    SH
    688302
    -0.57%
    SZ
    000513
    -0.45%
    HK
    01513
    -1.17%

    Innovative drug concept stocks collectively declined, Ausun Pharm hit the limit down

    Innovative drug concept stocks collectively fell, Ausun Pharm hit the limit down, SDKX dropped over 10%, Thalys, DEZHAN HEALTHCARE, and Hinova had significant declines

    Zhitong·
    SZ
    000813
    -0.51%
    SH
    688302
    -0.57%
    SH
    603229
    -0.73%
    Zhitong·
    SZ
    000813
    -0.51%
    SH
    688302
    -0.57%
    SH
    603229
    -0.73%
    © 2025 Longbridge｜Disclaimer